Who is benefiting from the amyloid hypothesis of Alzheimer’s? | STAT
https://www.statnews.com/2025/02/11/amyloid-hypothesis-alzheimers-research-lecanemab-aduhelm/
One group's influence, prestige, networking, and prolific writings help enforce a singular scientific and commercial vision for Alzheimer’s.
One idea has driven Alzheimer’s treatment — but to whose benefit?
https://www.statnews.com/2025/02/11/amyloid-hypothesis-alzheimers-research-lecanemab-aduhelm/
One group's influence, prestige, networking, and prolific writings help enforce a singular scientific and commercial vision for Alzheimer’s.